GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (CHIX:NOVOBc) » Definitions » Owner Earnings per Share (TTM)

Novo Nordisk AS (CHIX:NOVOBC) Owner Earnings per Share (TTM) : 21.42 (As of Sep. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Novo Nordisk AS Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Novo Nordisk AS's Owner Earnings per Share (TTM) ended in Sep. 2024 was kr21.42. It's Price-to-Owner-Earnings ratio for today is 36.84.


The historical rank and industry rank for Novo Nordisk AS's Owner Earnings per Share (TTM) or its related term are showing as below:

CHIX:NOVOBc' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.66   Med: 23.47   Max: 57.08
Current: 36.84


During the past 13 years, the highest Price-to-Owner-Earnings ratio of Novo Nordisk AS was 57.08. The lowest was 12.66. And the median was 23.47.


CHIX:NOVOBc's Price-to-Owner-Earnings is ranked worse than
63.19% of 432 companies
in the Drug Manufacturers industry
Industry Median: 26.825 vs CHIX:NOVOBc: 36.84

Novo Nordisk AS's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was kr6.12. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was kr21.20. It's PE Ratio (TTM) ratio for today is 37.22.

Novo Nordisk AS's EPS without NRI for the three months ended in Sep. 2024 was kr6.12. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was kr21.20. It's PE Ratio without NRI ratio for today is 37.22.


Novo Nordisk AS Owner Earnings per Share (TTM) Historical Data

The historical data trend for Novo Nordisk AS's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Owner Earnings per Share (TTM) Chart

Novo Nordisk AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.97 9.28 9.83 13.26 19.23

Novo Nordisk AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.22 19.23 21.49 25.60 21.43

Competitive Comparison of Novo Nordisk AS's Owner Earnings per Share (TTM)

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk AS's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Price-to-Owner-Earnings falls into.



Novo Nordisk AS Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Novo Nordisk AS's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income 94,721
Depreciation, Depletion and Amortization 16,901
Change In Deferred Tax 24,533
5Y Average of Maintenance Capital Expenditure 20,479
Change In Working Capital -20,697
Shares Outstanding (Diluted Average) 4,461

1. Start with "Net Income" from income statement. Novo Nordisk AS's Net Income for the trailing twelve months (TTM) ended in Sep. 2024 was kr94,721 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Novo Nordisk AS's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Sep. 2024 was kr16,901 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Novo Nordisk AS's Change In Deferred Tax for the trailing twelve months (TTM) ended in Sep. 2024 was kr24,533 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = kr20,479 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Novo Nordisk AS's 5-Year Average Maintenance Capital Expenditure = kr20,479 Mil

5. "Change In Working Capital" is from cashflow statement. Novo Nordisk AS's Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2024 was kr-20,697 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Novo Nordisk AS's Shares Outstanding (Diluted Average) for the months ended in Sep. 2024 was 4460.500 Mil.

Novo Nordisk AS's Onwer Earnings Per Share for Sep. 2024 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 94721 +16901+24533
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-20479.396726277+-20697)/4460.500
=21.42

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=789.10/21.42
=36.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Novo Nordisk AS Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk AS Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk AS Headlines

No Headlines